Skip to content

Effects of Head Elevation by a Bed on Sleep-disordered Breathing

Effects of Head Elevation by an Adjustable Bed on Sleep-disordered Breathing

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01785199
Enrollment
60
Registered
2013-02-07
Start date
2013-10-31
Completion date
2013-12-31
Last updated
2013-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive Sleep Apnea, Sleep-disordered Breathing

Keywords

apnea-hypopnea index, obstructive sleep apnea, body posture, ultra-wideband

Brief summary

Sleep is known to be a dynamic state of consciousness that is characterized by rapid fluctuations in autonomic activity as well as changes in body postures. Body postures during sleep influence the severity of sleep-disordered breathing because a supine position is associated with an increase in upper airway collapsibility and thus an increase in frequency and duration of snoring and apnea. Use of an adjustable bed to elevate patients' head might improve those conditions. The purpose of the present study is to determine whether use of an automatic adjustable bed is associated with reducing sleep-disordered breathing in patients with suspected obstructive sleep apnea (OSA) due to upper airway problems.

Detailed description

From the Chest and Otorhinolaryngology Department, patients with symptomatic sleep-disordered breathing will be referred to the Sleep Center. After an interview these subjects will undergo a full-night polysomnography (PSG). Patients who are eligible for this study will sleep on an automatic adjustable bed with a second PSG performed within the next one month. The automatic device is initiated when the patient suffers from apnea ≥ 10 seconds, which is detected by an ultra-wideband (UWB) sensor placed under the bed. The head will be slightly elevated at an angle of 10 degrees lasting 10 seconds and then be put down softly. Parameters of sleep efficiency and architecture, apnea-hypopnea index (AHI), and oxygen saturation will be obtained during each PSG. According to the severity, enrolled patients will be classified into 4 groups as normal (AHI \< 5), mild OSA (AHI between 5 and 15), moderate OSA (AHI between 15 and 30) and severe OSA (AHI \> 30). Using an automatic adjustable bed will improve sleep-disordered breathing with a reduction of AHI score is assumed. The minimal sample size is estimated to be 14 subjects per group with the intention of providing 80% power and an overall two-sided 5% type I error. A total of 60 subjects (15 subjects per group) will be enrolled to achieve the necessary number of evaluable subjects, anticipating roughly a 10% drop-out rate. Informed written consent will be obtained from all subjects. This study was approved by the Mackay Memorial Hospital Institutional Review Board.

Interventions

PROCEDUREHead elevation by an automatic adjustable bed

The automatic device is initiated when the patient suffers from apnea ≥ 10 seconds, which is detected by an ultra-wideband (UWB) sensor placed under the bed. The head will be slightly elevated at an angle of 10 degrees lasting 10 seconds and then be put down softly.

Sponsors

Seda Chemical Products Co., Ltd.
CollaboratorUNKNOWN
Mackay Memorial Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Subjects known to have snoring or sleep-disordered breathing

Exclusion criteria

* Refusal to participate * Pregnancy * Psychiatric disorders * Clinical instability in the previous month

Design outcomes

Primary

MeasureTime frameDescription
Reduction of AHI score.Two full-night PSGs will be performed within one monthUsing an automatic adjustable bed will improve sleep-disordered breathing with a reduction of AHI score is assumed.

Countries

Taiwan

Contacts

Primary ContactChing-Lung Liu, MD
lraphael.tw@yahoo.com.tw+886-2-28094661

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026